Uncategorized
Watson files ANDAs despite lawsuits
Watson Laboratories Inc., a subsidiary of Watson Pharmaceuticals Inc., has filed abbreviated new drug
applications (ANDAs) with the FDA seeking approval to market bimatoprost ophthalmic solution 0.01% and bimatoprost
ophthalmic solution 0.03%.